1. Scrip
  2. >>Business

As Tecentriq Growth Slows, Roche’s Imminent TIGIT Readout Is Crucial

Aims To Challenge Keytruda Dominance

 
• By Andrew McConaghie

One of the year’s most important trial readouts is for Roche’s potential first-in-class TIGIT inhibitor, tiragolumab, and could help reverse a slowdown in blockbuster immunotherapy Tecentriq's growth.

Roche_HQ
Roche's SKYSCRAPER 1 trial aims to improve on the overall survival benchmark set in NSCLC by Keytruda. • Source: Alamy

Roche could be just weeks away from revealing pivotal data from its combination of Tecentriq and its new TIGIT inhibitor, tiragolumab, in non-small cell lung cancer – a major ‘binary event’ that could either be a huge disappointment or signal a new challenge to Merck & Co's runaway immuno-oncology market leader Keytruda.

A clear win in the study would help boost the company’s sales growth prospects from its newer cancer drugs portfolio, especially as the PD-L1 blockbuster Tecentriq (atezolizumab) showed

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Atara Does An About Face As FDA Lifts Ebvallo Hold

 
• By Alaric DeArment

The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.